Summary
Definition
History and exam
Key diagnostic factors
- disease progression
- weakness
- altered sensation
- decreased deep tendon reflexes
Other diagnostic factors
- incoordination
- age 40 to 60 years
- preceding infection
- absence of exposure to neuropathy-causing drugs
- dyspnea
- facial weakness
- dysarthria
- dysphagia
- urinary incontinence
- urinary urgency or hesitancy
- impotence
- orthostatic hypotension
- papilledema
- vision loss
- spasticity
- ataxia
Risk factors
- male gender
- autoimmune diseases
- diabetes
- infection
- monoclonal gammopathy of undetermined significance (MGUS)
Diagnostic investigations
Investigations to consider
- nerve biopsy
- MRI spine
- nerve ultrasound
- ELISA or Western blot to detect autoantibodies
- clinical trial of immunosuppressant
Treatment algorithm
Contributors
Authors VIEW ALL
Professor of Neurology
Department of Neurology
Washington University School of Medicine
St. Louis
MO
Disclosures
GL is on the medical advisory board for Alnylam Pharmaceuticals and a consultant for Gerson Lehrman Group. GL is an author of a reference cited in this monograph.
Peer reviewers VIEW ALL
Partner
Phoenix Neurological Associates Ltd
Phoenix
AZ
Disclosures
TL declares that he has no competing interests.
Professor
Cochrane Neuromuscular Disease Group
MRC Centre for Neuromuscular Disease
National Hospital for Neurology and Neurosurgery
London
UK
Disclosures
RACH has held or holds consultancies with companies that produce intravenous immunoglobulin (CSL Behring, LFB, Octapharma, Kedrion, and Talecris) and with other companies that produce immunomodulatory drugs (Biogen-Idec and Ares-Serono). RACH has received grants from the UK Department of Health for the Cochrane Neuromuscular Disease Review Group, Sandoz (now Novartis), and Ares-Serono. RACH is an author of a number of references cited in this monograph.
Professor
CHU Dupuytren
Service et Laboratoire de Neurologie
Limoges
France
Disclosures
Not disclosed.
Use of this content is subject to our disclaimer